It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Subscribe To Our Newsletter & Stay Updated
